About 75 Percent of NFL Players Who Died in 2008 to 2023 Had CTE, a Bias-Adjusted Estimate Suggests
A Boston University team adjusted for who donates brains and estimates 74.5 percent of 2,362 deceased former players had CTE. That is below the 94 percent in donors and still high, with caveats.
Wednesday, October 28, 2026/3 min read

Chronic traumatic encephalopathy, or CTE, has been found in the brains of former football players for years, but one question has stalled the debate: how common is it really? Most of what is known comes from donated brains, and players with symptoms were more likely to be donated. A study published on Wednesday tries to correct for that, and lands at roughly three in four.
The paper, "Bias-adjusted prevalence of chronic traumatic encephalopathy among deceased National Football League players", appears in JAMA Network Open and was released under embargo until 11 a.m. Eastern on 28 October, according to a Boston University School of Medicine release. It estimates that 74.5 percent of NFL players who died between 2008 and 2023 had CTE neuropathology.
How did the researchers get to 74.5 percent?
They started with 2,362 former NFL players who died in that period, identified through death certificate records in the National Death Index. Of 387 whose brains were examined, 362, or 94 percent, had some degree of CTE. The authors say that figure overstates the rate, because players with cognitive symptoms were about five times more likely to have their brains donated.
Using that ratio, they adjusted the donor figure down to an estimate for all 2,362. The JAMA Network summary notes selection bias inflates donor-based estimates, but "does not fully explain the high burden of CTE neuropathology" among these players. The authors add that CTE is found in less than 1 percent of donors to community brain banks.
What does the number not tell us?
Several things. The estimate covers deceased former players only; it says nothing about how many living or current players have CTE. Having the pathology does not mean someone had symptoms, and not everyone with it develops them. And the adjustment rests on an estimated selection ratio, which is the central uncertainty. Medical Xpress points out that the same group's August paper in The BMJ gave a much wider range, 25 to 98 percent, for players who died from 2016 to 2021.
CTE can only be definitively diagnosed after death, which is why the research is retrospective. Lead author Julia Gallini says more effort is needed to diagnose CTE during life and to treat its symptoms. Earlier studies cited in the coverage found that NFL players develop dementia at about four times the population rate.
Who is the study about, and who is it not?
It is about professional players who died within a particular 16-year span. It does not measure risk for amateur, school or college players, nor for people who played other contact sports, and it cannot say what level of exposure causes the disease. The work was funded by the National Institute on Aging, the National Institute of Neurological Disorders and Stroke and the Concussion and CTE Foundation, which the release discloses. The authors acknowledge the findings may cause concern for living players and their families, and the release lists support lines including the NFL Life Line and the foundation's HelpLine.
This is reporting on a study, not medical advice. Anyone worried about head injuries, memory or mood changes in themselves or a family member should speak with a clinician who knows their history, and decisions about playing or returning to contact sport belong with a doctor, not a headline.
The next steps are the ones the authors name: better ways to diagnose CTE while people are alive, treatment for symptoms, and larger, less biased samples. Until those arrive, the best-supported statement is a cautious one: the true rate in former professionals is high, and nobody yet knows exactly how high.
Published in The Outspoken Digest
Editorial desk
Outspoken Digest Health DeskMedicine, public health and the research behind the headlines, read carefully.
Newsletter
The Digest, in your inbox
One edition, sent when it is ready. No noise, and your address is never passed on.
Read Next
More Health →
Adding Tarlatamab to Durvalumab Maintenance Lifted Median Survival to 21.1 Months in Small Cell Lung Cancer
Oct 27, 2026/2 min read

ACOG's New Menopause Guideline Backs Hormone Therapy, Adds Non-Hormonal Drugs and Rejects Soy and Herbal Supplements
Oct 26, 2026/3 min read

Personalized mRNA Melanoma Vaccine Plus Keytruda Cut Recurrence or Death Risk 42 Percent in Phase 3 Trial
Oct 25, 2026/3 min read

Heart Failure and Heart Attack Admissions Rose Faster Where US Cannabis Was Legalised, Study Reports
Oct 23, 2026/2 min read